» Articles » PMID: 20668832

Estimated Glomerular Filtration Rate and Albuminuria Are Independent Predictors of Cardiovascular Events and Death in Type 2 Diabetes Mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

Overview
Journal Diabetologia
Specialty Endocrinology
Date 2010 Jul 30
PMID 20668832
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Aims/hypothesis: We investigated effects of renal function and albuminuria on cardiovascular outcomes in 9,795 low-risk patients with diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Methods: Baseline and year 2 renal status were examined in relation to clinical and biochemical characteristics. Outcomes included total cardiovascular disease (CVD), cardiac and non-cardiac death over 5 years.

Results: Lower estimated GFR (eGFR) vs eGFR ≥90 ml min⁻¹ 1.73 m⁻² was a risk factor for total CVD events: (HR [95% CI] 1.14 [1.01-1.29] for eGFR 60-89 ml min⁻¹ 1.73 m⁻²; 1.59 [1.28-1.98] for eGFR 30-59 ml min⁻¹ 1.73 m⁻²; p < 0.001; adjusted for other characteristics). Albuminuria increased CVD risk, with microalbuminuria and macroalbuminuria increasing total CVD (HR 1.25 [1.01-1.54] and 1.19 [0.76-1.85], respectively; p = 0.001 for trend) when eGFR ≥90 ml min⁻¹ 1.73 m⁻². CVD risk was further modified by renal status changes over the first 2 years. In multivariable analysis, 77% of the effect of eGFR and 81% of the effect of albumin:creatinine ratio were accounted for by other variables, principally low HDL-cholesterol and elevated blood pressure.

Conclusions/interpretation: Reduced eGFR and albuminuria are independent risk factors for cardiovascular events and mortality rates in a low-risk population of mainly European ancestry. While their independent contributions to CVD risk appear small when other risk factors are considered, they remain excellent surrogate markers in clinical practice because they capture risk related to a number of other characteristics. Therefore, both should be considered when assessing prognosis and treatment strategies in patients with diabetes, and both should be included in risk models.

Citing Articles

Insights into the molecular underpinning of type 2 diabetes complications.

Singh A, Bocher O, Zeggini E Hum Mol Genet. 2025; 34(6):469-480.

PMID: 39807636 PMC: 11891870. DOI: 10.1093/hmg/ddae203.


Association between serum β2-microglobulin and left ventricular hypertrophy in patients with type 2 diabetes mellitus: A cross-sectional study.

Zhang Y, Peng G, Leng W, Li Y, Li H, Zhou L J Diabetes. 2024; 16(8):e13599.

PMID: 39155680 PMC: 11331034. DOI: 10.1111/1753-0407.13599.


The Cardiac-Kidney-Liver (CKL) syndrome: the "real entity" of type 2 diabetes mellitus.

Katsiki N, Kolovou G, Melidonis A, Banach M Arch Med Sci. 2024; 20(1):207-215.

PMID: 38414467 PMC: 10895975. DOI: 10.5114/aoms/183070.


Precision prognostics for cardiovascular disease in Type 2 diabetes: a systematic review and meta-analysis.

Ahmad A, Lim L, Morieri M, Tam C, Cheng F, Chikowore T Commun Med (Lond). 2024; 4(1):11.

PMID: 38253823 PMC: 10803333. DOI: 10.1038/s43856-023-00429-z.


Albuminuria: An Underappreciated Risk Factor for Cardiovascular Disease.

Barzilay J, Farag Y, Durthaler J J Am Heart Assoc. 2024; 13(2):e030131.

PMID: 38214258 PMC: 10926810. DOI: 10.1161/JAHA.123.030131.


References
1.
Stehouwer C, Lambert J, Donker A, van Hinsbergh V . Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 1997; 34(1):55-68. DOI: 10.1016/s0008-6363(96)00272-6. View

2.
Valmadrid C, Klein R, Moss S, Klein B . The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000; 160(8):1093-100. DOI: 10.1001/archinte.160.8.1093. View

3.
Festa A, DAgostino R, Howard G, Mykkanen L, Tracy R, Haffner S . Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int. 2000; 58(4):1703-10. DOI: 10.1046/j.1523-1755.2000.00331.x. View

4.
Keech A, Simes R, Barter P, Best J, Scott R, Taskinen M . Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366(9500):1849-61. DOI: 10.1016/S0140-6736(05)67667-2. View

5.
Vaziri N, Navab M, Fogelman A . HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol. 2010; 6(5):287-96. DOI: 10.1038/nrneph.2010.36. View